616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia

Phase 1 2 multi center open label clinical study to evaluate the safety pharmacokinetics and efficacy of zefamenib in patients with relapsed refractory acute leukemia

Phase 1 open label multi center trial of RPT1G in patients with Relapsed Refractory Acute Myeloid Leukemia and high risk Myelodysplastic Syndromes neoplasms

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1 mutated or KMT2A rearranged Acute Myeloid Leukemia Preliminary results from the Phase 1b etctn 10596 study

QHRD107 CDK9 Inhibitor venetoclax and azacitidine combination therapy 107VA regimen in relapsed refractory Acute Myeloid Leukemia Data updates and subgroup analysis

Multiarm Phase I study of the cyclin dependent kinase CDK4 6 inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Venetoclax cladribine plus low dose cytarabine for relapsed refractory Acute Myeloid Leukemia A multicenter randomized phase II Study

Preliminary pharmacokinetic and MRD results from AML patients treated with 7 and 14 day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

A dose optimization phase 1b 2 study evaluating mipletamig formerly APVO436 a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia AML in patients unfit for intensive chemotherapy

Preliminary safety and efficacy of the frida study Iadademstat and gilteritinib in FLT3 mutated relapsed refractory acute myeloid leukemia

Efficacy and safety results of TQB3909 a novel BCL 2 inhibitor in combination with azacitidine for patients with myeloid malignancies

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy Results from the cadenza study

A phase 1 2 first in human multicenter open label trial evaluating the safety tolerability and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia AML

First in human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia The Phase 1 siltuxilam study